StratifiCare Reaches Grand Final of the 2026 UAiTED Innovation Competition

StratifiCare Pte Ltd is pleased to announce its selection as an official finalist in the 2026 UAiTED Innovation Competition.

Organized by the University Alliance in Taiwan for Innovation Production and Education Development (UAiTED), the annual competition highlights high-potential startups incubated across partner academic institutions in Asia, fostering cross-regional collaboration and accelerating technological impact. The official finalist announcement can be viewed on the UAiTED News Platform.

Predictive Clarity in Liver Cancer Therapy StratifiCare’s pitch centres on StratifiREY, a novel companion diagnostic panel built to solve a major challenge in hepatocellular carcinoma (HCC) management. While yttrium-90 (Y90) transarterial radioembolization (TARE) is an increasingly used local radiation therapy, evaluating patient response historically required waiting 3 to 6 months post-procedure.

StratifiREY utilizes a multi-biomarker blood assay to analyze patient immune profiles prior to TARE procedure execution. Validated through clinical studies at the National Cancer Centre Singapore (NCCS), the platform equips multi-disciplincary tumour boards with actionable predictive data, helping clinicians identify likely non-responders beforehand and guiding patients toward alternative, effective treatment pathways without delay.

StratifiREY was engineered to replace trial-and-error treatment selection with immediate biological insights. We look forward to presenting our technology at the Grand Final in Taipei and expanding our clinical and commercial partnerships across the region.

To learn more about StratifiREY and StratifiCare’s diagnostic pipeline, visit www.stratificare.com.